Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Specialty pharma company Knight Therapeutics nets $70mm in bought deal

03 Jan 2017

Executive Summary

Knight Therapeutics Inc. (specialty pharmaceuticals) netted $70mm in an up-sized bought deal financing consisting of 10mm (originally planned for 7.5mm; includes full exercise of 1.3mm over-allotment option) common shares at $7.40 ($Cdn10; 5% discount). The company will use the proceeds for future growth.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By